We are monitoring the impact of COVID-19 on North America Plasma Protein Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

North America Plasma Protein Therapeutics Market Research Report – Segmented By Product Type, Application & Country (The United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2022 to 2027)

Published: January, 2022
ID: 206
Pages: 135

North America Plasma Protein Therapeutics Market Size (2022 to 2027)

The North American Plasma Protein Therapeutics Market is currently valued at USD 9294.69 Million in 2022 and held the most dominant share in the global market and is estimated to reach USD 13956.71 Million by the end of 2027, registering a CAGR of 8.47% between 2022 to 2027.

The rising prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders are the primary reasons driving the expansion of the plasma protein therapeutics market in North America. Along with these considerations, the growing geriatric population in North America is a significant driver of market expansion, as the old are more susceptible to neurological problems.

Furthermore, biotechnology and pharmaceutical businesses are increasing their efforts in research and development initiatives, encouraging market growth. The plasma protein segment's current research and development is expected to drive its utilization in various applications. In the subsequent years, the increased use of therapeutic protein medicines in treating a wide range of clinical complaints is expected to provide this market with unique growth prospects.

To improve patients' quality of life and ensure donor safety, the plasma protein business has relied on quality and innovations. Plasma obtained through apheresis or whole blood donation processing can be assembled or divided into plasma protein products containing one or more pure plasma proteins or directly transfused to patients.

However, factors such as tight processing requirements for plasma protein products and a lack of acceptable reimbursement mechanisms are hampering the market's expansion. Furthermore, plasma collection standards in underdeveloped countries do not meet the fractionator's needs. To maintain the quality of their operations, these places have strict laws and regulations, starting with the quality of the raw materials. Plasma fractionators are specifically designed for this purpose. In addition to the fact that it is a complicated technology, raw material costs and numerous safety requirements influence the cost of these things. As a result, maintaining access to plasma protein therapy requires appropriate funding.

This research report on the North America plasma protein therapeutics market has been segmented and sub-segmented into the following categories:

By Type: 

  • Immunoglobulins
  • Albumin
  • Coagulation Factor
  • Alpha-1 Proteinase Inhibitor
  • Others

By Application: 

  • Hemophilia
  • Primary Immunodeficiency Disorder
  • Idiopathic Thrombocytopenic Purpura
  • Secondary Immunodeficiency
  • Others

By Country: 

  • The United States
  • Canada
  • Rest of North America

Geographically, the North American regional market is likely to remain the leader in the global plasma protein therapeutics market throughout the forecast period. A growing number of people are suffering from autoimmune and neurological diseases, supporting market growth. The United States is expected to be the primary market in this region. In addition, budgets for healthcare are under increasing strain. Plasma protein therapies have been dragged into the landscape of Health Technology Assessments (HTA), including the prospective use of cost-utility analysis (CUA) to distribute reimbursement monies, thanks to funding through reimbursement pathways from commercial and public payers.

The region's growing senior population further expands the patient pool, as the elderly are more susceptible to neurological illnesses. Furthermore, favorable government initiatives, rising blood donor awareness, the availability of improved protein fractioning processes, higher per capita income in developed countries, and an increase in the number of research collaborations are all projected to boost market expansion in the region.

KEY MARKET PLAYERS:

Grifols, CSL Behring, Baxter, Krdrion, China Biologics, Octapharma, Chendu Inst, and Shire Plc play a leading role in the North American Plasma Protein Therapeutics Market.

1. Introduction                                                                                                 

                1.1 Market Definition                                                                                    

                1.2 Study Deliverables                                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                                          

                1.4 General Study Assumptions                                                                                

2. Research Methodology                                                                                                           

                2.1 Introduction                                                                                               

                2.2 Research Phases                                                                                      

                                2.2.1 Secondary Research                                                                           

                                2.2.2 Primary Research                                                                 

                                2.2.3 Econometric Modelling                                                                      

                                2.2.4 Expert Validation                                                                  

                2.3 Analysis Design                                                                                         

                2.4 Study Timeline                                                                                          

3. Overview                                                                                                       

                3.1 Executive Summary                                                                                

                3.2 Key Inferences                                                                                         

                3.3 New Developments                                                                                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                                                    

                4.1 Market Drivers                                                                                          

                4.2 Market Restraints                                                                                    

                4.3 Key Challenges                                                                                         

                4.4 Current Opportunities in the Market                                                                                              

5. Market Segmentation                                                                                                              

                5.1 By Type                                                                                        

                                5.1.1 Immunoglobulins                                                                 

                                5.1.2 Albumin                                                                   

                                5.1.3 Coagulation Factors                                                                             

                                5.1.4 Alpha-1 proteinase inhibitor                                                                            

                                5.1.5 Others                                                                      

                5.2 By Application                                                                                           

                                5.2.1 Hemophilia                                                                             

                                5.2.2 Primary Immunodeficiency Disorder                                                                           

                                5.2.3 Idiopathic Thrombocytopenic Purpura                                                                        

                                5.2.4 Secondary Immunodeficiency                                                                        

                                5.2.5 Others                                                                      

6. Geographical Analysis                                                                                                              

                6.1 Introduction                                                                                               

                6.2 United States                                                                                            

                6.3 Canada                                                                                         

7. Strategic Analysis                                                                                                       

                7.1 PESTLE analysis                                                                                         

                                7.1.1 Political                                                                     

                                7.1.2 Economic                                                                 

                                7.1.3 Social                                                                         

                                7.1.4 Technological                                                                         

                                7.1.5 Legal                                                                          

                                7.1.6 Environmental                                                                       

                7.2 Porter’s Five analysis                                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                                        

                                7.2.2 Bargaining Power of Consumers                                                                    

                                7.2.3 Threat of New Entrants                                                                     

                                7.2.4 Threat of Substitute Products and Services                                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                                     

8. Market Leaders' Analysis                                                                                                        

                8.1 CSL Behring                                                                

                                8.1.1 Overview                                                                 

                                8.1.2 Product Analysis                                                                   

                                8.1.3 Strategic Evaluation and Operations                                                                            

                                8.1.4 Financial analysis                                                                  

                                8.1.5 Legal issues                                                                             

                                8.1.6 Recent Developments                                                                       

                                8.1.7 SWOT analysis                                                                       

                                8.1.8 Analyst View                                                                          

                8.2 Baxter                                                                           

                8.3 Biotest                                                                          

                8.4 China Biologics                                                                          

                8.5 Grifols                                                                           

                8.6 Kedrion                                                                        

                8.7 Octapharma                                                                               

                8.8 Shire Plc.                                                                      

                8.9 Chengdu Inst.                                                                            

9. Competitive Landscape                                                                                                           

                9.1 Market share analysis                                                                                            

                9.2 Merger and Acquisition Analysis                                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                                         

                9.4 New Product Launches                                                                                         

10. Expert Opinions                                                                                                        

                10.1 Market Outlook                                                                                     

                10.2 Investment Opportunities                                                                                 

Appendix                                                                                                           

                a) List of Tables                                                                                

                b) List of Figures                                                                                              

  1. North America Plasma Protein Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  2. North America Plasma Protein Therapeutics Market, By Application From 2022 - 2027 (USD Million)
  3. North America Immunoglobulins Market, By Region, From 2022 - 2027 (USD Million)
  4. North America Albumin Market, By Region, From 2022 - 2027 (USD Million)
  5. North America Coagulation Factors Market, By Region, From 2022 - 2027 (USD Million)
  6. North America Alpha-1 proteinase inhibitor Market, By Region, From 2022 - 2027 (USD Million)
  7. North America Others Market, By Region, From 2022 - 2027 (USD Million)
  8. North America Hemophilia Market, By Region, From 2022 - 2027 (USD Million)
  9. North America Primary Immunodeficiency Disorder Market, By Region, From 2022 - 2027 (USD Million)
  10. North America Idiopathic Thrombocytopenic Purpura Market, By Region, From 2022 - 2027 (USD Million)
  11. North America Secondary Immunodeficiency Market, By Region, From 2022 - 2027 (USD Million)
  12. North America Others Market, By Region, From 2022 - 2027 (USD Million)
  13. United States Plasma Protein Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  14. Canada Plasma Protein Therapeutics Market, By Type, From 2022 - 2027 (USD Million)
  15. United States Plasma Protein Therapeutics Market, By Application, From 2022 - 2027 (USD Million)
  16. Canada Plasma Protein Therapeutics Market, By Application, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample